Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance.

<h4>Background</h4>Evidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function. A reduced endothelial progenitor cell (EPC) number is associated with impaired glucose tolera...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Valentina Spigoni, Angela Picconi, Monia Cito, Valentina Ridolfi, Sabrina Bonomini, Chiara Casali, Ivana Zavaroni, Luigi Gnudi, Marco Metra, Alessandra Dei Cas
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2012
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/d0c2c141123543ff8cc35f48394d56ee
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!